Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXCR4 Modified BCMA CAR-T in Refractory/Relapsed Multiple Myeloma
NCT04727008Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CXCR4 modified anti-BCMA CAR T cells in multiple myeloma (MM), sponsored by Sichuan University. Primary endpoints: Dose Limiting Toxicities at 2 years and Incidence and severity of adverse events and serious adverse events at 24 months. Started Sep 2022; status: recruiting.
02
Drugs
CXCR4 modified anti-BCMA CAR T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04727008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727008.